Elevai Labs (NASDAQ:ELAB) vs. Inventiva (NASDAQ:IVA) Head-To-Head Survey

Inventiva (NASDAQ:IVA) and Elevai Labs (NASDAQ:ELAB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.

Profitability

This table compares Inventiva and Elevai Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Elevai Labs	-223.41%	-124.93%	-85.10%

Valuation & Earnings

This table compares Inventiva and Elevai Labs”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$15.62 million	10.35	-$119.51 million	N/A	N/A
Elevai Labs	$2.45 million	1.52	-$4.30 million	($62.00)	-0.02

Elevai Labs has lower revenue, but higher earnings than Inventiva.

Volatility and Risk

Inventiva has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Elevai Labs has a beta of -3.28, indicating that its share price is 428% less volatile than the S&P 500.

Insider and Institutional Ownership

19.1% of Inventiva shares are held by institutional investors. Comparatively, 22.2% of Elevai Labs shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 1.3% of Elevai Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Inventiva and Elevai Labs, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	0	1	4	0	2.80
Elevai Labs	0	0	0	0	0.00

Inventiva presently has a consensus target price of $12.60, suggesting a potential upside of 309.09%. Given Inventiva’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Inventiva is more favorable than Elevai Labs.

Summary

Inventiva beats Elevai Labs on 10 of the 12 factors compared between the two stocks.

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

About Elevai Labs

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.